News from novogen ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 11, 2016, 07:00 ET Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New...


Jun 14, 2016, 07:00 ET Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in...


May 02, 2016, 07:00 ET Novogen Provides Update On Development Of Cantrixil

US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of...


Mar 16, 2016, 10:02 ET Novogen Receives R&D Tax Incentive Cash Refund

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the...


Feb 19, 2016, 12:11 ET Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that a patent for the superbenzopyran (SBP) family,...


Feb 05, 2016, 02:20 ET Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr...


Dec 09, 2015, 04:59 ET Novogen Appoints Dr James Garner as Chief Executive Officer

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive...


Nov 24, 2015, 07:00 ET Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial

Novogen engages Novotech as CRO for upcoming Phase 1 clinical study Cantrixil Phase 1 clinical trial to be conducted in patients with...


Nov 12, 2015, 07:00 ET Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead...


Nov 10, 2015, 05:34 ET Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of preclinical studies which confirm the...


Aug 31, 2015, 07:30 ET Novogen Announces The Outcome Of A Comprehensive Science Review

US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed its comprehensive scientific review has identified...


Jul 29, 2015, 07:54 ET Newly Appointed Acting CEO Outlines Immediate Plans for Novogen

US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking...


Jul 22, 2015, 07:00 ET Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board

Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an...


Jul 16, 2015, 07:30 ET Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration...


Jul 13, 2015, 04:30 ET Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that...


Jun 24, 2015, 07:00 ET Novogen Announces the Chairman's Address at the Company's General Meeting

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) announced today the Chairman's Address at the Company's General Meeting. ...


Jun 24, 2015, 07:00 ET Anisina on Track to Enter Clinic in 2016

US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that its candidate cytotoxic chemotherapy...


Jun 12, 2015, 07:00 ET Novogen to Present at Bio International Convention Philadelphia 2015

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced today that Novogen Group CEO, Graham Kelly, will be...


Jun 04, 2015, 08:00 ET Studies Confirm TRXE-009 Crosses the Blood-brain Barrier

US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to...


Jun 03, 2015, 07:00 ET Novogen Expands Board with Two New Appointments

Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of two new...


Jun 02, 2015, 07:00 ET Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of Shortfall

US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the non-renounceable pro-rata rights...


May 28, 2015, 07:00 ET ATM Technology Extended with New Patent Lodgement

US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the lodgement with the US Patent Office ...


May 27, 2015, 07:00 ET Novogen to Present at Brain Tumor Biotech Summit 2015

US-Australian drug discovery and development company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), announced today that it will present at the Brain...


May 26, 2015, 07:00 ET Novogen to Present at the 2015 Marcum Microcap Conference

US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that it will present at the 2015 Marcum ...


May 18, 2015, 07:00 ET Novogen to Present at Hong Kong Investor Conference

US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that company CEO, Dr Graham Kelly, will ...